StockWatch
·

BOSTON SCIENTIFIC CORP Q2 FY26 Results

BSXQ2 FY26 Results
Filing
MetricValue ($ M)Q1 FY26Q2 FY25
Revenue5.4K4.6%7.5%
Total Income5.4K4.6%7.5%
Expenditure4.3K4.0%0.5%
PBT1.1K8.8%12.7%
Net Profit907.0032.4%13.8%
OPM21.65%0.48pp5.46pp
NPM16.67%9.11pp0.92pp
EPS0.6231.1%14.8%
View full financials

Boston Scientific Reports Q2 2026 Results with 7.5% Net Sales Growth

29 Jul 2026 · 29 Jul, 4:06 pm

Summary

Boston Scientific announced strong second quarter 2026 financial results, with net sales reaching $5.442 billion, a 7.5 percent increase on a reported basis and 7.0 percent on an organic basis year-over-year. GAAP net income attributable to common stockholders was $907 million, or $0.61 per share, up from $797 million, or $0.53 per share, in the prior year. Adjusted EPS also saw a significant increase to $0.86 from $0.75. Management expressed confidence in the company's long-term growth, driven by disciplined execution and strategic investments in high-impact opportunities.

Key Highlights

  1. 1

    Boston Scientific generated net sales of $5.442 billion during the second quarter of 2026, growing 7.5 percent on a reported basis and 7.0 percent on an operational and organic basis compared to the prior year period.

  2. 2

    The company reported GAAP net income attributable to Boston Scientific common stockholders of $907 million or $0.61 per share, compared to $797 million or $0.53 per share a year ago.

  3. 3

    Adjusted EPS for the second quarter of 2026 was $0.86 per share, an increase from $0.75 per share in the prior year period.

  4. 4

    MedSurg segment net sales increased by 5.9 percent on a reported basis, while Cardiovascular segment net sales grew by 8.3 percent on a reported basis compared to the prior year.

  5. 5

    The company completed a $2 billion accelerated share repurchase program, repurchasing approximately 40 million shares.

  6. 6

    Boston Scientific invested $1.5 billion in MiRus LLC, securing an equity stake and an exclusive option to acquire the MiRus TAVR business.

  7. 7

    Clinical trial results for the FARAPULSE Pulsed Field Ablation (PFA) system met all safety and effectiveness endpoints, demonstrating statistical superiority over anti-arrhythmic drugs.

Management Comments

M

Mike Mahoney

Our team delivered a solid quarter while continuing to navigate a dynamic environment. We are focused on disciplined execution and prioritizing investments in our highest-impact opportunities, and we remain confident in Boston Scientific's long-term growth, anchored by our category leadership strategy and our commitment to meaningful innovation for patients and physicians.

Informational and educational content only. Not investment advice.